Fusion protein comprising BP26 and antigenic polypeptide
The present disclosure relates to a fusion protein comprising BP26 and an antigenic polypeptide, and to a nanoarchitecture comprising same. A vaccine composition comprising the fusion protein, nanoarchitecture, or combination thereof of the present disclosure can be used to effectively prevent or treat pathogens or cancer, and thus can be used as a multi-purpose vaccine platform.
1 . A nanoarchitecture comprising a fusion protein comprising BP26 and an antigenic polypeptide,
wherein the antigenic polypeptide is linked to the C-terminus of the BP26, and no antigenic polypeptide is linked to the N-terminus of the BP26; and
wherein the nanoarchitecture comprises 8 or 16 copies of the fusion protein.
2 . A vaccine composition comprising the nanoarchitecture of claim 1 .
3 . The vaccine composition of claim 2 , wherein the vaccine composition is for preventing infection from an infectious pathogen.
4 . The vaccine composition of claim 2 , wherein the vaccine composition is for a cancer vaccine.
5 . The vaccine composition of claim 2 , wherein the vaccine composition further comprises an adjuvant.
6 . The nanoarchitecture of claim 1 , wherein the BP26 comprises the amino acid sequence of SEQ ID NO: 1 or 2.
7 . The nanoarchitecture of claim 1 , wherein the antigen is a pathogen-derived antigen or a tumor-derived antigen.
8 . The nanoarchitecture of claim 7 , wherein the pathogen is selected from the group consisting of a virus, a bacterium, a Rickettsia , a fungus, and a protozoa.
9 . The nanoarchitecture of claim 7 , wherein the pathogen-derived antigenic polypeptide is M2e.
10 . The nanoarchitecture of claim 9 , wherein the M2e comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, or 6.
11 . The nanoarchitecture of claim 1 , wherein the fusion protein comprises at least one copy of the antigenic polypeptide.
12 . The nanoarchitecture of claim 1 , wherein the antigenic polypeptides are continuously or discontinuously linked in the fusion protein.